Cargando…

(66)Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [(66)Ga]Ga-NOTA-PEG(2)-RM26

Molecular imaging of the gastrin-releasing peptide receptor (GRPR) could improve patient management in prostate cancer. This study aimed to produce gallium-66 (T(½) = 9.5 h) suitable for radiolabeling, and investigate the imaging properties of gallium-66 labeled GRPR-antagonist NOTA-PEG(2)-RM26 for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinne, Sara S., Abouzayed, Ayman, Gagnon, Katherine, Tolmachev, Vladimir, Orlova, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878787/ https://www.ncbi.nlm.nih.gov/pubmed/33574368 http://dx.doi.org/10.1038/s41598-021-82995-7

Ejemplares similares

Preclinical Evaluation of (99m)Tc-Labeled GRPR Antagonists maSSS/SES-PEG(2)-RM26 for Imaging of Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2021)

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [(68)Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation
por: Lundmark, Fanny, et al.
Publicado: (2023)

Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2020)

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer
por: Mitran, Bogdan, et al.
Publicado: (2019)

The GRPR Antagonist [(99m)Tc]Tc-maSSS-PEG(2)-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer
por: Baun, Christina, et al.
Publicado: (2020)

Phase I Trial of [(99m)Tc]Tc-maSSS-PEG(2)-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
por: Chernov, Vladimir, et al.
Publicado: (2023)

High Contrast PET Imaging of GRPR Expression in Prostate Cancer Using Cobalt-Labeled Bombesin Antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2017)

Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

Trastuzumab cotreatment improves survival of mice with PC‐3 prostate cancer xenografts treated with the GRPR antagonist (177)Lu‐DOTAGA‐PEG(2)‐RM26
por: Mitran, Bogdan, et al.
Publicado: (2019)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
por: Abouzayed, Ayman, et al.
Publicado: (2019)

The Use of a Non-Conventional Long-Lived Gallium Radioisotope (66)Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer—Optimization of the Affinity towards PSMA by Linker Modification in Murine Model
por: Lundmark, Fanny, et al.
Publicado: (2020)

The Effect of Mini-PEG-Based Spacer Length on Binding and Pharmacokinetic Properties of a (68)Ga-Labeled NOTA-Conjugated Antagonistic Analog of Bombesin
por: Varasteh, Zohreh, et al.
Publicado: (2014)

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
por: Rinne, Sara S., et al.
Publicado: (2019)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Preclinical Evaluation of [(68)Ga]Ga-DFO-ZEGFR:2377: A Promising Affibody-Based Probe for Noninvasive PET Imaging of EGFR Expression in Tumors
por: Oroujeni, Maryam, et al.
Publicado: (2018)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

(68)Ga-NOTA PET imaging for gastric emptying assessment in mice
por: Chen, Xueyan, et al.
Publicado: (2021)

Radiosynthesis and preclinical evaluation of [(68)Ga]Ga-NOTA-folate for PET imaging of folate receptor β-positive macrophages
por: Moisio, Olli, et al.
Publicado: (2020)

PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [(68)Ga]Ga-NODAGA-AMBA and [(44)Sc]Sc-NODAGA-AMBA
por: Kálmán-Szabó, Ibolya, et al.
Publicado: (2022)

Design, Synthesis, and Preliminary Evaluation of [(68)Ga]Ga-NOTA-Insulin as a PET Probe in an Alzheimer’s Disease Mouse Model
por: Taubel, Jillissa C., et al.
Publicado: (2022)

Evaluation of Tumor-Targeting Properties of an Antagonistic Bombesin Analogue RM26 Conjugated with a Non-Residualizing Radioiodine Label Comparison with a Radiometal-Labelled Counterpart
por: Oroujeni, Maryam, et al.
Publicado: (2019)

PET Imaging of Hepatocellular Carcinoma Using ZD2-((68)Ga-NOTA)
por: Sergeeva, Olga, et al.
Publicado: (2023)

In Vitro and In Vivo Evaluation of a (18)F-Labeled High Affinity NOTA Conjugated Bombesin Antagonist as a PET Ligand for GRPR-Targeted Tumor Imaging
por: Varasteh, Zohreh, et al.
Publicado: (2013)

Prospective comparison of [(18)F]AlF-NOTA-octreotide PET/MRI to [(68)Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients
por: Boeckxstaens, Lennert, et al.
Publicado: (2023)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

(68)Ga-BBN-RGD PET/CT for GRPR and Integrin α(v)β(3) Imaging in Patients with Breast Cancer
por: Zhang, Jingjing, et al.
Publicado: (2018)

(66)Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?
por: Amor-Coarasa, Alejandro, et al.
Publicado: (2018)

A 66–76 GHz Wide Dynamic Range GaAs Transceiver for Channel Emulator Application
por: Zhou, Peigen, et al.
Publicado: (2022)

(68)Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [(68)Ga]Ga-RM2
por: Chastel, Adrien, et al.
Publicado: (2021)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

(68)Ga-Labeling: Laying the Foundation for an Anti-Radiolytic Formulation for NOTA-sdAb PET Tracers
por: Baudhuin, Henri, et al.
Publicado: (2021)

[(68)Ga]Ga-RM2 PET/CT reveals small distant metastases not detected by conventional imaging in primary estrogen receptor-positive breast cancer
por: Michalski, Kerstin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i8ds9s5h49tgaeb9b02ldkkvlu